Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 828 Neoplasms 573 Prostatic Neoplasms 464 Lung Neoplasms 325 Carcinoma, Non-Small-Cell Lung 297 Colorectal Neoplasms 291 Leukemia, Myeloid, Acute 221 Brain Neoplasms 190 Multiple Myeloma 187 Neoplasm Metastasis 180 Pancreatic Neoplasms 169 Carcinoma, Hepatocellular 151 Melanoma 150 Squamous Cell Carcinoma of Head and Neck 139 Precursor Cell Lymphoblastic Leukemia-Lymphoma 139 Head and Neck Neoplasms 139 Ovarian Neoplasms 136 Glioblastoma 133 Uterine Cervical Neoplasms 125 Sarcoma 115 Lymphoma 115 Recurrence 113 Colonic Neoplasms 109 Rectal Neoplasms 108 Glioma 108 Hematologic Neoplasms 107 Triple Negative Breast Neoplasms 103 Urinary Bladder Neoplasms 102 Stomach Neoplasms 102 Carcinoma, Renal Cell 93

Interventions

atezolizumab 1 Radiotherapy 1 Radiosurgery 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡